MAPK1 and neoplasm: Collectively, the present results represent the first time that KCa3.1 activators are a possible target for overcoming IL-10-mediated escape from tumor immune surveillance in the TME, through their inhibition of the IL-10 in TAMs via the ERK-CREB and JNK-c-Jun cascades.